Swiss pharmaceutical giant Novartis announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...

Shares of DexCom Inc. DXCM slid 3.59% to $66.11 Monday, on what proved to be an all-around rough trading session for the ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $100 from $115 and keeps an Outperform rating on the shares as part of a ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $107.00. The company’s shares closed last Friday at $66.14.

The Food and Drug Administration (FDA) has cleared diabetes-management firm DexCom's (DXCM) new continuous glucose monitoring (CGM) system. The San Diego, Calif.-based firm said Thursday that its ...

What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

Trends indicate increasing adoption among adults aged 20+, with significant expansion in the male CGM market. Key players include Dexcom, Inc., Abbott Laboratories, and Medtronic. The report offers ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong fourth-quarter 2024 performance and a series of favorable coverage decisions ...

DexCom experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief Commercial Officer.

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes ...

Dexcom’s first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be ...